Cleerly is trying to make coronary computed tomography angiography (CCTA) a standard part of preventative heart care.
The New York-based company’s CCTA software, cleared by the US Food and Drug Administration in 2020, relies on machine-learning and 3D-imaging techniques to analyze, characterize and quantify coronary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?